Lupin Launches Generic Atrovent Nasal Spray In US Market

Lupin Ltd. on Friday said it has launched Ipratropium Bromide nasal solution in 0.03% and 0.06% strengths in the US, a generic version of Boehringer Ingelheim's Atrovent nasal spray. The drug is used to treat rhinorrhea, or runny nose, linked to both allergic and nonallergic rhinitis.

The 0.03% solution is approved for adults and children over six years for perennial rhinitis, while the 0.06% version is approved for rhinorrhea associated with the common cold and seasonal allergies in children above five and adults.

The total US market for the drug is estimated at $63 million annually, Lupin said in its filing.